Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionhigh voltage-gated calcium channel activity

CACNA1F CACNA1S CACNA1I

5.22e-05141073GO:0008331
GeneOntologyMolecularFunctionprotein kinase activity

TRIB2 WNK1 MYLK3 CSK PIK3CB MTOR TNK2 PRKCI ROS1 PRKCZ MAP2K1 MAP2K3

8.94e-0560010712GO:0004672
GeneOntologyMolecularFunctionphospholipid-hydroperoxide glutathione peroxidase activity

GPX4 CP

1.69e-0441072GO:0047066
GeneOntologyMolecularFunctionmetalloendopeptidase activity involved in amyloid precursor protein catabolic process

ADAM19 ADAM10

1.69e-0441072GO:1902945
GeneOntologyMolecularFunctionphosphotransferase activity, alcohol group as acceptor

TRIB2 WNK1 MYLK3 CSK PIK3CB MTOR TNK2 PRKCI ROS1 PRKCZ MAP2K1 MAP2K3

4.15e-0470910712GO:0016773
GeneOntologyMolecularFunctiontransferase activity, transferring phosphorus-containing groups

CTU2 TRIB2 POLR2A WNK1 MYLK3 CSK PIK3CB MTOR TNK2 PRKCI ROS1 PRKCZ MAP2K1 MAP2K3

4.81e-0493810714GO:0016772
GeneOntologyMolecularFunctionendopeptidase activity

ADAM19 CASP2 CPS1 ADAM10 F11 CFB ADAMTS20 PRSS42P PLG

5.11e-044301079GO:0004175
GeneOntologyMolecularFunctionprotein serine/threonine kinase activity

WNK1 MYLK3 PIK3CB MTOR TNK2 PRKCI PRKCZ MAP2K1 MAP2K3

6.63e-044461079GO:0004674
GeneOntologyMolecularFunctionprotein serine kinase activity

WNK1 PIK3CB MTOR TNK2 PRKCI PRKCZ MAP2K1 MAP2K3

7.54e-043631078GO:0106310
GeneOntologyMolecularFunctionpeptidase activity

ADAM19 CASP2 AGBL5 CPS1 ADAM10 F11 CFB AGBL3 ADAMTS20 PRSS42P PLG

7.68e-0465410711GO:0008233
GeneOntologyMolecularFunctionkinase activity

TRIB2 WNK1 MYLK3 CSK PIK3CB MTOR TNK2 PRKCI ROS1 PRKCZ MAP2K1 MAP2K3

8.03e-0476410712GO:0016301
GeneOntologyMolecularFunctionprotein tyrosine kinase activity

CSK TNK2 ROS1 MAP2K1 MAP2K3

1.11e-031451075GO:0004713
DomainVDCCAlpha1

CACNA1F CACNA1S CACNA1I

2.13e-05101073IPR002077
DomainPKC

PRKCI PRKCZ

3.25e-0521072IPR012233
DomainKinase-like_dom

TRIB2 WNK1 MYLK3 CSK PIK3CB MTOR TNK2 PRKCI ROS1 PRKCZ MAP2K1 MAP2K3

6.39e-0554210712IPR011009
DomainVDCC_L_a1su

CACNA1F CACNA1S

1.94e-0441072IPR005446
DomainChannel_four-helix_dom

CACNA1F CACNA1S NALCN CACNA1I

3.18e-04571074IPR027359
Domain-

CACNA1F CACNA1S NALCN CACNA1I

3.18e-045710741.20.120.350
DomainProt_kinase_dom

TRIB2 WNK1 MYLK3 CSK TNK2 PRKCI ROS1 PRKCZ MAP2K1 MAP2K3

5.02e-0448910710IPR000719
DomainIon_trans_dom

CACNA1F CACNA1S NALCN CACNA1I KCNH5

5.03e-041141075IPR005821
DomainIon_trans

CACNA1F CACNA1S NALCN CACNA1I KCNH5

5.03e-041141075PF00520
DomainPROTEIN_KINASE_DOM

TRIB2 WNK1 MYLK3 CSK TNK2 PRKCI ROS1 PRKCZ MAP2K1 MAP2K3

5.35e-0449310710PS50011
DomainPan_app

F11 PLG

6.70e-0471072IPR003609
DomainCa_chan_IQ

CACNA1F CACNA1S

6.70e-0471072SM01062
DomainCa_chan_IQ

CACNA1F CACNA1S

6.70e-0471072PF08763
DomainPAN

F11 PLG

6.70e-0471072PS50948
DomainVDCC_a1su_IQ

CACNA1F CACNA1S

6.70e-0471072IPR014873
DomainGPHH

CACNA1F CACNA1S

6.70e-0471072PF16905
DomainGPHH_dom

CACNA1F CACNA1S

6.70e-0471072IPR031649
DomainPAN_1

F11 PLG

6.70e-0471072PF00024
DomainPROTEIN_KINASE_ATP

WNK1 MYLK3 CSK TNK2 PRKCI ROS1 PRKCZ MAP2K1 MAP2K3

1.29e-034591079PS00107
DomainPep_M12B_propep

ADAM19 ADAM10 ADAMTS20

1.44e-03391073PF01562
DomainPeptidase_M12B_N

ADAM19 ADAM10 ADAMTS20

1.44e-03391073IPR002870
DomainProtein_kinase_ATP_BS

MYLK3 CSK TNK2 PRKCI ROS1 PRKCZ MAP2K1 MAP2K3

1.52e-033791078IPR017441
DomainDISINTEGRIN_1

ADAM19 ADAM10 ADAMTS20

1.55e-03401073PS00427
DomainReprolysin

ADAM19 ADAM10 ADAMTS20

1.55e-03401073PF01421
DomainADAM_MEPRO

ADAM19 ADAM10 ADAMTS20

1.55e-03401073PS50215
DomainDISINTEGRIN_2

ADAM19 ADAM10 ADAMTS20

1.55e-03401073PS50214
DomainPeptidase_M12B

ADAM19 ADAM10 ADAMTS20

1.55e-03401073IPR001590
DomainDisintegrin_dom

ADAM19 ADAM10 ADAMTS20

1.66e-03411073IPR001762
DomainPB1

PRKCI PRKCZ

2.83e-03141072SM00666
DomainPB1

PRKCI PRKCZ

2.83e-03141072PF00564
DomainPB1

PRKCI PRKCZ

2.83e-03141072PS51745
DomainPB1_dom

PRKCI PRKCZ

2.83e-03141072IPR000270
DomainTRYPSIN_HIS

F11 CFB PRSS42P PLG

2.91e-031031074IPR018114
DomainTRYPSIN_SER

F11 CFB PRSS42P PLG

3.23e-031061074PS00135
DomainPI3/4_kinase_CS

PIK3CB MTOR

3.25e-03151072IPR018936
Domain-

GBF1 PSD4

3.25e-031510721.10.1000.11
DomainSec7

GBF1 PSD4

3.25e-03151072PF01369
DomainSec7_alpha_orthog

GBF1 PSD4

3.25e-03151072IPR023394
DomainTRYPSIN_HIS

F11 CFB PRSS42P PLG

3.34e-031071074PS00134
Domain-

PIK3CB MTOR

3.70e-031610721.10.1070.11
DomainSEC7

GBF1 PSD4

3.70e-03161072PS50190
DomainPI3Kc

PIK3CB MTOR

3.70e-03161072SM00146
DomainSec7

GBF1 PSD4

3.70e-03161072SM00222
DomainSec7_dom

GBF1 PSD4

3.70e-03161072IPR000904
DomainPeptidase_S1A

F11 CFB PRSS42P PLG

4.06e-031131074IPR001314
DomainFN3

MYOM1 OBSL1 TRIM9 ASTN1 ROS1

4.25e-031851075SM00060
DomainTRYPSIN_DOM

F11 CFB PRSS42P PLG

4.33e-031151074PS50240
DomainTryp_SPc

F11 CFB PRSS42P PLG

4.60e-031171074SM00020
DomainPI3_PI4_kinase

PIK3CB MTOR

4.69e-03181072PF00454
DomainPI3_4_KINASE_1

PIK3CB MTOR

4.69e-03181072PS00915
DomainPI3_4_KINASE_2

PIK3CB MTOR

4.69e-03181072PS00916
DomainPI3/4_kinase_cat_dom

PIK3CB MTOR

4.69e-03181072IPR000403
DomainPI3_4_KINASE_3

PIK3CB MTOR

4.69e-03181072PS50290
DomainTrypsin_dom

F11 CFB PRSS42P PLG

5.18e-031211074IPR001254
DomainTrypsin

F11 CFB PRSS42P PLG

5.18e-031211074PF00089
DomainPeptidase_S1_PA

F11 CFB PRSS42P PLG

5.49e-031231074IPR009003
PathwayKEGG_MEDICUS_REFERENCE_VGCC_CA2_APOPTOTIC_PATHWAY

CACNA1F CACNA1S CACNA1I VDAC1

1.15e-0523884M47666
PathwayWP_4HYDROXYTAMOXIFEN_DEXAMETHASONE_AND_RETINOIC_ACIDS_REGULATION_OF_P27_EXPRESSION

PIK3CB MTOR MAP2K1 MAP2K3

1.62e-0525884M39574
PathwayWP_EGFR1_SIGNALING_PATHWAY

WNK1 CSK PIK3CB TNK2 PRKCI PRKCZ MAP2K1 MAP2K3

2.23e-05188888MM15828
PathwayWP_ALZHEIMERS_DISEASE

CACNA1F CACNA1S WNT2 ADAM10 CALML6 PIK3CB MTOR MAP2K1 VDAC1

3.55e-05261889M42565
PathwayKEGG_MEDICUS_REFERENCE_AREG_EGFR_PI3K_SIGNALING_PATHWAY

AREG PIK3CB MTOR

3.74e-0511883M47501
PathwayKEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_VGCC_CA2_APOPTOTIC_PATHWAY_N01004

CACNA1F CACNA1S VDAC1

8.14e-0514883M47692
PathwayPID_CXCR3_PATHWAY

PIK3CB MTOR MAP2K1 MAP2K3

1.45e-0443884M222
PathwayWP_GLIOBLASTOMA_SIGNALING

PIK3CB PRKCI PRKCZ MAP2K1 MAP2K3

1.67e-0483885M39637
PathwayWP_TRANSLATION_INHIBITORS_IN_CHRONICALLY_ACTIVATED_PDGFRA_CELLS

PIK3CB MTOR MAP2K1 MAP2K3

1.89e-0446884M39805
PathwayWP_ALZHEIMERS_DISEASE_AND_MIRNA_EFFECTS

CACNA1F CACNA1S WNT2 ADAM10 CALML6 PIK3CB MTOR MAP2K1 VDAC1

1.95e-04326889M39379
PathwayKEGG_INSULIN_SIGNALING_PATHWAY

CALML6 PIK3CB MTOR PRKCI PRKCZ MAP2K1

2.13e-04137886M18155
PathwayREACTOME_SIGNALING_BY_RECEPTOR_TYROSINE_KINASES

POLR2A ITGB3 AREG CSK PIK3CB MTOR TNK2 PRKCZ PLG MAP2K1

2.70e-044188810MM15587
PathwayWP_GNAQ_PATHWAYS_IN_PORTWINE_STAIN

MTOR MAP2K1 MAP2K3

2.88e-0421883M48342
PathwayWP_COMPLEMENT_SYSTEM

CD55 ITGB3 F11 CFB PLG

3.31e-0496885M39581
PathwayWP_MICRORNAS_IN_CARDIOMYOCYTE_HYPERTROPHY

MYLK3 PIK3CB MTOR MAP2K1 MAP2K3

3.81e-0499885MM15905
PathwayKEGG_GNRH_SIGNALING_PATHWAY

CACNA1F CACNA1S CALML6 MAP2K1 MAP2K3

4.18e-04101885M1979
PathwayREACTOME_SIGNALING_BY_RECEPTOR_TYROSINE_KINASES

POLR2A ADAM10 ITGB3 AREG CSK PIK3CB MTOR TNK2 PRKCZ PLG MAP2K1

4.60e-045328811M27870
PathwayWP_MICRORNAS_IN_CARDIOMYOCYTE_HYPERTROPHY

MYLK3 PIK3CB MTOR MAP2K1 MAP2K3

4.78e-04104885M39625
PathwayKEGG_MEDICUS_REFERENCE_CA2_ENTRY_VOLTAGE_GATED_CA2_CHANNEL

CACNA1F CACNA1S CACNA1I

4.89e-0425883M47948
PathwayWP_INSULIN_SIGNALING

PIK3CB MTOR PRKCI PRKCZ MAP2K1 MAP2K3

4.90e-04160886MM15956
PathwayWP_INSULIN_SIGNALING

PIK3CB MTOR PRKCI PRKCZ MAP2K1 MAP2K3

4.90e-04160886M39482
PathwayWP_COMPLEMENT_SYSTEM_IN_NEURONAL_DEVELOPMENT_AND_PLASTICITY

CD55 ITGB3 CFB PRKCI PRKCZ

5.22e-04106885M42535
PathwayWP_EGFEGFR_SIGNALING

CSK MTOR TNK2 PRKCI PRKCZ MAP2K1

5.23e-04162886M39334
PathwayKEGG_MEDICUS_VARIANT_SCRAPIE_CONFORMATION_PRPSC_TO_VGCC_CA2_APOPTOTIC_PATHWAY

CACNA1F CACNA1S

5.69e-046882M47762
PathwayKEGG_MEDICUS_PATHOGEN_YERSINIA_YOPP_J_TO_TLR2_4_MAPK_SIGNALING_PATHWAY

MAP2K1 MAP2K3

5.69e-046882M47636
PathwayKEGG_GLIOMA

CALML6 PIK3CB MTOR MAP2K1

7.18e-0465884M1835
PathwayKEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION

CACNA1F CACNA1S CALML6 MYLK3 MAP2K1

7.57e-04115885M9387
PathwayKEGG_CALCIUM_SIGNALING_PATHWAY

CACNA1F CACNA1S CALML6 MYLK3 CACNA1I VDAC1

8.58e-04178886M2890
PathwayKEGG_COMPLEMENT_AND_COAGULATION_CASCADES

CD55 F11 CFB PLG

9.00e-0469884M16894
PathwayPID_NEPHRIN_NEPH1_PATHWAY

PIK3CB PRKCI PRKCZ

9.31e-0431883M193
PathwayPID_CDC42_PATHWAY

MTOR TNK2 PRKCZ MAP2K3

9.50e-0470884M81
PathwayKEGG_MEDICUS_VARIANT_AMPLIFIED_PDGFR_TO_PI3K_SIGNALING_PATHWAY

PIK3CB MTOR

1.05e-038882M47399
PathwayKEGG_MEDICUS_VARIANT_AMPLIFIED_EGFR_TO_PI3K_SIGNALING_PATHWAY

PIK3CB MTOR

1.05e-038882M47394
PathwayKEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_RET_TO_PI3K_SIGNALING_PATHWAY

PIK3CB MTOR

1.05e-038882M47715
Pubmed

mTORC2 phosphorylates protein kinase Cζ to regulate its stability and activity.

MTOR PRKCI PRKCZ

3.06e-075110324375676
Pubmed

DIDO as a Switchboard that Regulates Self-Renewal and Differentiation in Embryonic Stem Cells.

POLR2A PRKCI PRKCZ

3.06e-075110328330622
Pubmed

Evolutionary insights into T-type Ca2+ channel structure, function, and ion selectivity from the Trichoplax adhaerens homologue.

CACNA1F CACNA1S CACNA1I

1.70e-068110328330839
Pubmed

A Single Adaptable Cochaperone-Scaffold Complex Delivers Nascent Iron-Sulfur Clusters to Mammalian Respiratory Chain Complexes I-III.

GBF1 GPX4 WNK1 GFPT1 NOSIP CSK GLG1 PWP2 MAP2K1 MAP2K3 CPSF3 QSOX2

1.91e-066861101228380382
Pubmed

Glutamylation of the DNA sensor cGAS regulates its binding and synthase activity in antiviral immunity.

AGBL5 AGBL3 TTLL4

2.55e-069110326829768
Pubmed

International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels.

CACNA1F CACNA1S CACNA1I

2.55e-069110316382099
Pubmed

Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers.

ADAM19 POLR2A WNK1 CALML6 GFPT1 PRMT6 CSK PRKCI PRKCZ MAP2K1 RPL3L KCNH5

3.60e-067301101234857952
Pubmed

IL-7Rα glutamylation and activation of transcription factor Sall3 promote group 3 ILC development.

AGBL5 AGBL3 TTLL4

6.63e-0612110328794449
Pubmed

Requirements for pseudosubstrate arginine residues during autoinhibition and phosphatidylinositol 3,4,5-(PO₄)₃-dependent activation of atypical PKC.

PRKCI PRKCZ

9.91e-062110225035426
Pubmed

The voltage-dependent anion channel is a receptor for plasminogen kringle 5 on human endothelial cells.

PLG VDAC1

9.91e-062110212736244
Pubmed

Activation of protein kinase C-ζ in pancreatic β-cells in vivo improves glucose tolerance and induces β-cell expansion via mTOR activation.

MTOR PRKCZ

9.91e-062110221911744
Pubmed

PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.

PRKCI PRKCZ

9.91e-062110224786829
Pubmed

The signaling axis atypical protein kinase C λ/ι-Satb2 mediates leukemic transformation of B-cell progenitors.

PRKCI PRKCZ

9.91e-062110230610188
Pubmed

Atypical protein kinase C isoforms differentially regulate directional keratinocyte migration during wound healing.

PRKCI PRKCZ

9.91e-062110230660448
Pubmed

The endometria of women with endometriosis exhibit dysfunctional expression of complement regulatory proteins during the mid secretory phase.

CD55 ITGB3

9.91e-062110229153978
Pubmed

Atypical protein kinase C activity is required for extracellular matrix degradation and invasion by Src-transformed cells.

PRKCI PRKCZ

9.91e-062110219492416
Pubmed

PKC zeta controls DNA topoisomerase-dependent human caspase-2 pre-mRNA splicing.

CASP2 PRKCZ

9.91e-062110218166155
Pubmed

Ceramide regulates atypical PKCzeta/lambda-mediated cell polarity in primitive ectoderm cells. A novel function of sphingolipids in morphogenesis.

PRKCI PRKCZ

9.91e-062110217105725
Pubmed

Single-chain structure of human ceruloplasmin: the complete amino acid sequence of the whole molecule.

CP PLG

9.91e-06211026582496
Pubmed

The roles of phosphatidylinositol 3-kinase and protein kinase Czeta for thrombopoietin-induced mitogen-activated protein kinase activation in primary murine megakaryocytes.

PRKCZ MAP2K1

9.91e-062110211535599
Pubmed

Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC).

MTOR PRKCI

9.91e-062110221373201
Pubmed

Somatic Mutation Patterns in Hemizygous Genomic Regions Unveil Purifying Selection during Tumor Evolution.

POLR2A INTS10

9.91e-062110228027311
Pubmed

Characterization of Lhx9, a novel LIM/homeobox gene expressed by the pioneer neurons in the mouse cerebral cortex.

LHX9 LHX2

9.91e-062110210330499
Pubmed

Structure-based mapping of DAF active site residues that accelerate the decay of C3 convertases.

CD55 CFB

9.91e-062110217395591
Pubmed

Regulation of asymmetric division and CD8+ T lymphocyte fate specification by protein kinase Cζ and protein kinase Cλ/ι.

PRKCI PRKCZ

9.91e-062110225617472
Pubmed

Atypical PKC-zeta and PKC-iota mediate opposing effects on MCF-7 Na+/K+ATPase activity.

PRKCI PRKCZ

9.91e-062110215887250
Pubmed

Protein kinase C iota promotes glycolysis via PI3K/AKT/mTOR signalling in high grade serous ovarian cancer.

MTOR PRKCI

9.91e-062110239276277
Pubmed

Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells.

MTOR ROS1

9.91e-062110231053160
Pubmed

Repletion of atypical protein kinase C following RNA interference-mediated depletion restores insulin-stimulated glucose transport.

PRKCI PRKCZ

9.91e-062110216644736
Pubmed

Expression of the atypical protein kinase C (aPKC) isoforms iota/lambda and zeta during mouse embryogenesis.

PRKCI PRKCZ

9.91e-062110216931174
Pubmed

LHX2 promotes malignancy and inhibits autophagy via mTOR in osteosarcoma and is negatively regulated by miR-129-5p.

LHX2 MTOR

9.91e-062110231724536
Pubmed

Regulation of cell survival by atypical protein kinase C isozymes.

PRKCI PRKCZ

9.91e-062110212791393
Pubmed

Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells.

ITGB3 CSK

9.91e-062110216859511
Pubmed

aPKCλ/ι and aPKCζ contribute to podocyte differentiation and glomerular maturation.

PRKCI PRKCZ

9.91e-062110223334392
Pubmed

Atypical protein kinase C (aPKCzeta and aPKClambda) is dispensable for mammalian hematopoietic stem cell activity and blood formation.

PRKCI PRKCZ

9.91e-062110221653884
Pubmed

Two novel atypical PKC inhibitors; ACPD and DNDA effectively mitigate cell proliferation and epithelial to mesenchymal transition of metastatic melanoma while inducing apoptosis.

PRKCI PRKCZ

9.91e-062110229048609
Pubmed

Functional comparison of protein domains within aPKCs involved in nucleocytoplasmic shuttling.

PRKCI PRKCZ

9.91e-062110223213435
Pubmed

Interplay between MTOR and GPX4 signaling modulates autophagy-dependent ferroptotic cancer cell death.

GPX4 MTOR

9.91e-062110232457486
Pubmed

Oxysterol-binding protein-related protein 5 (ORP5) promotes cell proliferation by activation of mTORC1 signaling.

MTOR OSBPL5

9.91e-062110229358326
Pubmed

PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.

PIK3CB MTOR

9.91e-062110226549638
Pubmed

Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.

AREG MTOR

9.91e-062110225862847
Pubmed

Human placenta and trophoblasts simultaneously express three isoforms of atypical protein kinase-c.

PRKCI PRKCZ

9.91e-062110235124330
Pubmed

Albumin-induced epithelial-mesenchymal transition and ER stress are regulated through a common ROS-c-Src kinase-mTOR pathway: effect of imatinib mesylate.

CSK MTOR

9.91e-062110221367918
Pubmed

Chemical evidence that proteolytic cleavage causes the heterogeneity present in human ceruloplasmin preparations.

CP PLG

9.91e-0621102146197
Pubmed

A dual-activity topoisomerase complex regulates mRNA translation and turnover.

HIVEP2 GBF1 POLR2A HECTD4 CHD8 WNK1 MTOR TTLL4 SUMF1 OSBPL5 TNK2 TOP3B ZNF614 ZNF426

1.06e-0511051101435748872
Pubmed

Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.

RAPSN NR1I2 FBH1 MYLK3 TNK2 PRKCI PRKCZ KLHL26

2.52e-05372110822939624
Pubmed

Solution structure of atypical protein kinase C PB1 domain and its mode of interaction with ZIP/p62 and MEK5.

PRKCI PRKCZ

2.97e-053110215143057
Pubmed

MEK5, a new target of the atypical protein kinase C isoforms in mitogenic signaling.

PRKCI PRKCZ

2.97e-053110211158308
Pubmed

Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway.

MTOR TNK2

2.97e-053110232162707
Pubmed

Chromosomal localization of four MAPK signaling cascade genes: MEK1, MEK3, MEK4 and MEKK5.

MAP2K1 MAP2K3

2.97e-05311029465908
Pubmed

Binding of stromal derived factor-1alpha (SDF-1alpha) to CXCR4 chemokine receptor in normal human megakaryoblasts but not in platelets induces phosphorylation of mitogen-activated protein kinase p42/44 (MAPK), ELK-1 transcription factor and serine/threonine kinase AKT.

MAP2K1 MAP2K3

2.97e-053110210997882
Pubmed

A phosphoproteomic study reveals shp-1 cleavage reprograms LPS signaling via a PI-3K/NF-κB and mTORC1 related mechanism.

PIK3CB MTOR

2.97e-053110226206180
Pubmed

PKCtheta cooperates with atypical PKCzeta and PKCiota in NF-kappaB transactivation of T lymphocytes.

PRKCI PRKCZ

2.97e-053110217588663
Pubmed

PKCζ Is Essential for Pancreatic β-Cell Replication During Insulin Resistance by Regulating mTOR and Cyclin-D2.

MTOR PRKCZ

2.97e-053110226868297
Pubmed

Mutant HRAS as novel target for MEK and mTOR inhibitors.

MTOR MAP2K1

2.97e-053110226544513
Pubmed

Hepatitis E viral infection regulates estrogen signaling pathways: Inhibition of the cAMPK-PKA-CREB and PI3K-AKT-mTOR signaling pathways.

PIK3CB MTOR

2.97e-053110233128390
Pubmed

Binding of Myomesin to Obscurin-Like-1 at the Muscle M-Band Provides a Strategy for Isoform-Specific Mechanical Protection.

MYOM1 OBSL1

2.97e-053110227989621
Pubmed

Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.

MTOR MAP2K1

2.97e-053110225534823
Pubmed

22 genes from chromosome 17q21: cloning, sequencing, and characterization of mutations in breast cancer families and tumors.

ETV4 EZH1

2.97e-05311027774926
Pubmed

The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C.

PRKCI PRKCZ

2.97e-05311028797824
Pubmed

Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells.

MTOR VDAC1

2.97e-053110226655341
Pubmed

Adhesion-induced unclasping of cytoplasmic tails of integrin alpha(IIb)beta3.

MYOM1 ITGB3

2.97e-053110219117493
Pubmed

High expression of the "A Disintegrin And Metalloprotease" 19 (ADAM19), a sheddase for TNF-α in the mucosa of patients with inflammatory bowel diseases.

ADAM19 ADAM10

2.97e-053110223429442
Pubmed

The Par3/aPKC interaction is essential for end bud remodeling and progenitor differentiation during mammary gland morphogenesis.

PRKCI PRKCZ

2.97e-053110219528321
Pubmed

Potassium acts through mTOR to regulate its own secretion.

WNK1 MTOR

2.97e-053110231013253
Pubmed

Aberrant expression of the polarity complex atypical PKC and non-muscle myosin IIA in active and inactive inflammatory bowel disease.

PRKCI PRKCZ

2.97e-053110221667320
Pubmed

Rab2 interacts directly with atypical protein kinase C (aPKC) iota/lambda and inhibits aPKCiota/lambda-dependent glyceraldehyde-3-phosphate dehydrogenase phosphorylation.

PRKCI PRKCZ

2.97e-053110214570876
Pubmed

Molecular cross-talk between MEK1/2 and mTOR signaling during recovery of 293 cells from hypertonic stress.

MTOR MAP2K1

2.97e-053110215292274
Pubmed

Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway.

PIK3CB MTOR

2.97e-053110226780727
Pubmed

Atypical protein kinase C (PKCzeta/lambda) is a convergent downstream target of the insulin-stimulated phosphatidylinositol 3-kinase and TC10 signaling pathways.

PRKCI PRKCZ

2.97e-053110214734537
Pubmed

Polarity-dependent distribution of angiomotin localizes Hippo signaling in preimplantation embryos.

PRKCI PRKCZ

2.97e-053110223791731
Pubmed

Direct control of mitochondrial function by mTOR.

MTOR VDAC1

2.97e-053110220080789
Pubmed

WNK1 mediates amphiregulin-induced MMP9 expression and cell invasion in human extravillous trophoblast cells.

WNK1 AREG

2.97e-053110237544354
Pubmed

Control of MT1-MMP transport by atypical PKC during breast-cancer progression.

PRKCI PRKCZ

2.97e-053110224753582
Pubmed

Mammalian Target of Rapamycin 2 (MTOR2) and C-MYC Modulate Glucosamine-6-Phosphate Synthesis in Glioblastoma (GBM) Cells Through Glutamine: Fructose-6-Phosphate Aminotransferase 1 (GFAT1).

GFPT1 MTOR

2.97e-053110230771196
Pubmed

Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway.

PRKCI PRKCZ MAP2K1

3.37e-0520110311044099
Pubmed

Extracellular HIV-1 Tat protein induces a rapid and selective activation of protein kinase C (PKC)-alpha, and -epsilon and -zeta isoforms in PC12 cells.

PIK3CB PRKCI PRKCZ

3.93e-052111039446795
Pubmed

HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes.

PIK3CB PRKCI PRKCZ

4.54e-0522110311154208
Pubmed

Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases.

MAP2K1 MAP2K3

5.92e-05411028226933
Pubmed

Atypical protein kinase C is essential for embryonic vascular development in mice.

PRKCI PRKCZ

5.92e-054110233547760
Pubmed

Insulin promotes the association of heat shock protein 90 with the inositol 1,4,5-trisphosphate receptor to dampen its Ca2+ release activity.

CSK MTOR

5.92e-054110219147678
Pubmed

Rescue of atypical protein kinase C in epithelia by the cytoskeleton and Hsp70 family chaperones.

PRKCI PRKCZ

5.92e-054110219549684
Pubmed

(+)-Vitisin A inhibits osteoclast differentiation by preventing TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activation.

ITGB3 CSK

5.92e-054110224558484
Pubmed

The effects of intrinsic pathway protease deficiencies on plasminogen-deficient mice.

F11 PLG

5.92e-054110215985536
Pubmed

Expression of the LIM-homeodomain gene Lmx1a (dreher) during development of the mouse nervous system.

LHX9 LHX2

5.92e-054110212351192
Pubmed

Differential dephosphorylation of the protein kinase C-zeta (PKCζ) in an integrin αIIbβ3-dependent manner in platelets.

ITGB3 PRKCZ

5.92e-054110221645497
Pubmed

PIP3 but not PIP2 increases GLUT4 surface expression and glucose metabolism mediated by AKT/PKCζ/λ phosphorylation in 3T3L1 adipocytes.

PRKCI PRKCZ

5.92e-054110223749168
Pubmed

Beta-adrenergic-regulated phosphorylation of the skeletal muscle Ca(V)1.1 channel in the fight-or-flight response.

CACNA1F CACNA1S

5.92e-054110220937870
Pubmed

miR-221 regulates CD44 in hepatocellular carcinoma through the PI3K-AKT-mTOR pathway.

PIK3CB MTOR

5.92e-054110228442344
Pubmed

Integrins αvβ5 and αvβ3 promote latent TGF-β1 activation by human cardiac fibroblast contraction.

ITGB3 TGFBI

5.92e-054110224639195
Pubmed

Post-sepsis immunosuppression depends on NKT cell regulation of mTOR/IFN-γ in NK cells.

MTOR IL22

5.92e-054110232154791
Pubmed

Phosphorylated MARCKS: a novel centrosome component that also defines a peripheral subdomain of the cortical actin cap in mouse eggs.

PRKCI PRKCZ

5.92e-054110215766745
Pubmed

Control of Paneth Cell Fate, Intestinal Inflammation, and Tumorigenesis by PKCλ/ι.

PRKCI PRKCZ

5.92e-054110227653691
Pubmed

Epithelial aPKC deficiency leads to stem cell loss preceding metaplasia in colorectal cancer initiation.

PRKCI PRKCZ

5.92e-054110238815584
Pubmed

Anti-angiogenic effects of thioridazine involving the FAK-mTOR pathway.

ITGB3 MTOR

5.92e-054110223022044
Pubmed

Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.

F11 PLG

5.92e-05411028555184
Pubmed

Transcription factor Lhx2 is necessary and sufficient to suppress astrogliogenesis and promote neurogenesis in the developing hippocampus.

LHX9 LHX2

5.92e-054110221690374
Pubmed

Hydrogen sulfide and L-cysteine increase phosphatidylinositol 3,4,5-trisphosphate (PIP3) and glucose utilization by inhibiting phosphatase and tensin homolog (PTEN) protein and activating phosphoinositide 3-kinase (PI3K)/serine/threonine protein kinase (AKT)/protein kinase Cζ/λ (PKCζ/λ) in 3T3l1 adipocytes.

PRKCI PRKCZ

5.92e-054110221953448
Pubmed

WD-repeat-propeller-FYVE protein, ProF, binds VAMP2 and protein kinase Czeta.

PRKCI PRKCZ

5.92e-054110217313651
Pubmed

Zeta Inhibitory Peptide Disrupts Electrostatic Interactions That Maintain Atypical Protein Kinase C in Its Active Conformation on the Scaffold p62.

PRKCI PRKCZ

5.92e-054110226187466
GeneFamilyCalcium voltage-gated channel subunits

CACNA1F CACNA1S CACNA1I

1.54e-0426733253
GeneFamilyMitogen-activated protein kinase kinases

MAP2K1 MAP2K3

3.33e-047732653
GeneFamilyLIM class homeoboxes

LHX9 LHX2

1.03e-0312732522
GeneFamilyFibronectin type III domain containing

MYOM1 TRIM9 ASTN1 ROS1

4.00e-03160734555
CoexpressionGSE17186_CD21LOW_VS_CD21HIGH_TRANSITIONAL_BCELL_CORD_BLOOD_DN

HEATR1 EZH1 ITGB3 ZBTB1 CSK TNK2 MAP2K1 PSD4

1.71e-062001078M7193
CoexpressionGSE19401_NAIVE_VS_IMMUNIZED_MOUSE_PLN_FOLLICULAR_DC_DN

POLR2A GPX4 CFB CDC40 CSK PIK3CB GLG1

1.86e-052001077M7658
CoexpressionGSE14413_UNSTIM_VS_IFNB_STIM_NIH3T3_CELLS_UP

GBF1 TULP2 TRIM9 ADAMTS20 CPSF3 KCNH5

2.52e-051411076M466
CoexpressionAtlasDevelopingLowerUrinaryTract_e14.5_ bladder_emap-6668_top-relative-expression-ranked_500

MKRN3 SEC16B CELF4 MYOM1 WNT2 WRN CD55 ITGB3 ZBTB1 GFPT1 SUMF1

7.83e-0642210511DevelopingLowerUrinaryTract_e14.5_ bladder_emap-6668_500
ToppCellfacs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CACNA1F ABCA13 CPS1 LOXHD1 HMCN1 ADAMTS20 ROS1 MYO16

1.79e-0818410982cbed6462fea2622871bb7e49b0df3d984239281
ToppCellfacs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CACNA1F ABCA13 CPS1 LOXHD1 HMCN1 ADAMTS20 ROS1 MYO16

1.79e-081841098ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCellfacs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CACNA1F ABCA13 CPS1 LOXHD1 HMCN1 ADAMTS20 ROS1 MYO16

1.79e-0818410982b19a8c5f823e00812908b23e66bb4e563278aff
ToppCellAdult-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)-D122|Adult / Lineage, Cell type, age group and donor

OBSL1 CFB FCGBP ST6GALNAC3 PRKCI ROS1 PRKCZ

1.22e-07157109731d1bd9138c60e8485664ec4144f987226e3eef9
ToppCell390C-Lymphocytic-NK_cells-NK_cell_D3|NK_cells / Donor, Lineage, Cell class and subclass (all cells)

SEC16B ADAM19 WNT2 OBSL1 CP ST6GALNAC3

3.65e-0616810966501495b7ad252af330b18011696c43031541018
ToppCellfacs-Diaphragm-Limb_Muscle-24m|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

HIVEP2 MYOM1 UPK1A ABCA13 POLR2A NALCN

3.78e-06169109612bdc709bc000d7f9061ecd9fbd57233eaacb7e2
ToppCellFrontal_cortex-Neuronal-Excitatory-eN2(Slc17a7_Slc17a6)-Slc17a6-Excitatory_Neuron.Slc17a6.Reln_(Cajal-Retzius)-|Frontal_cortex / BrainAtlas - Mouse McCarroll V32

CACNA1F LHX9 DLEC1 GREB1 RPL3L

9.85e-0611610951bfd3b0ec4cb5a04c6dfe7861a544eb277e473a3
ToppCellFrontal_cortex-Neuronal-Excitatory-eN2(Slc17a7_Slc17a6)-Slc17a6-Excitatory_Neuron.Slc17a6.Reln_(Cajal-Retzius)|Frontal_cortex / BrainAtlas - Mouse McCarroll V32

CACNA1F LHX9 DLEC1 GREB1 RPL3L

9.85e-061161095a3dcd18807d14e207438f321be62797384fd3907
ToppCellFrontal_cortex-Neuronal-Excitatory-eN2(Slc17a7_Slc17a6)-Slc17a6|Frontal_cortex / BrainAtlas - Mouse McCarroll V32

CACNA1F LHX9 DLEC1 GREB1 RPL3L

9.85e-061161095685484ea4cbefb5aff5f0cd999fdfadc5a5676e1
ToppCellE16.5-samps-Mesenchymal-Myofibroblast-Proliferative_Immature_MyoFibroblast|E16.5-samps / Age Group, Lineage, Cell class and subclass

CACNA1S MYOM1 OBSL1 MYLK3 PRKCZ

2.05e-051351095ed0f94d3839eea3b60217c4352159ed481361f13
ToppCellfrontal_cortex-Neuronal-glutamatergic_neuron-L5_IT-L5_IT_ALM_Lypd1_Gpr88|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype

SEC16B TRIB2 LHX2 CACNA1I KCNH5

4.23e-0515710955aee90ad7aaa65fdabc23597451da5e48db8f4e6
ToppCelldroplet-Lung-3m-Hematologic-lymphocytic-Zbtb32+_B_cell-Zbtb32+_B_cell|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

CACNA1S CD55 CSK CACNA1I PRKCZ

4.77e-0516110957af3b0d4fc7967f6b3e2d255d23fd8b1fd01a7af
ToppCell390C-Lymphocytic-NK_cells-NK_cell_D3|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)

SEC16B WNT2 OBSL1 CP AREG

4.77e-0516110953e5a125a25d55bf27652f456239b00b315d54d91
ToppCelldroplet-Lung-3m-Hematologic-lymphocytic-Zbtb32+_B_cell|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

CACNA1S CD55 CSK CACNA1I PRKCZ

4.77e-05161109598be0cf8228496b31f7f3e0efd8787e95eb626d1
ToppCelldroplet-Lung-18m-Hematologic-lymphocytic-Zbtb32+_B_cell-Zbtb32+_B_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

CACNA1S UPK1A CD55 CACNA1I PRKCZ

5.68e-0516710953c3e1c31aacca48099693aea2efdfa22fc0e4af4
ToppCelldroplet-Lung-18m-Hematologic-lymphocytic-Zbtb32+_B_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

CACNA1S UPK1A CD55 CACNA1I PRKCZ

5.68e-05167109577a4d7ce44847c76074d4f5340d61b398fe43e6c
ToppCellBAL-Severe-cDC_5|Severe / Compartment, Disease Groups and Clusters

RAPSN CD55 AREG LHX2 MYLK3

5.84e-051681095857a80c217a5513553460798a625612031bc7bb7
ToppCelldroplet-Kidney-nan-3m-Lymphocytic-CD45____B_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CASP2 CD55 CACNA1I MAP2K1 PSD4

6.18e-0517010956210ee3bf29059e6149c047bb7e02c5f59441519
ToppCell3'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-club_cell-Club_(non-nasal)-Club_(non-nasal)_L.0.4.0.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TRIB2 CD55 CP XRCC2 FCGBP

6.53e-05172109563a91974b12c3f7f0c6bf66c30088d7fc07f5cea
ToppCell5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.4|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ABCA13 CD55 CP CFB FCGBP

6.71e-051731095176b956e71d98e8275d698b39437fc326e5fe449
ToppCelldroplet-Heart-HEART_(LV+RV_ONLY)-30m-Endothelial-leukocyte|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

WNT2 CP ITGB3 UGT8 PRKCZ

7.08e-051751095f6e1d7297a4dbb38e1ab4f738d91f0e62abaee69
ToppCell(03)_Secretory|World / shred by cell type and Timepoint

CD55 CP GFPT1 CFB FCGBP

7.28e-051761095cb7b1945788196ca79007f0768b6576ec885a0e5
ToppCellCOVID-19-kidney-PCT-S3-2|COVID-19 / Disease (COVID-19 only), tissue and cell type

CP CPS1 F11 NR1I2 PLG

7.28e-051761095b6497324e3e52f514ce556a3fa0c3011c45dcc7b
ToppCellCV-Severe-7|Severe / Virus stimulation, Condition and Cluster

ADAM19 ZNF407 ADAM10 GLG1 UGT8

7.47e-05177109582fdd6185b368f54f03de389427cbe3071d21a99
ToppCellwk_20-22-Hematologic-Meg-ery-Definitive_erythroblast|wk_20-22 / Celltypes from embryonic and fetal-stage human lung

HECTD4 CD55 WNK1 MAP2K3 QSOX2

8.52e-0518210950c77ef4556c1d1512ebe9077df858b28f9e38dd5
ToppCellwk_08-11-Mesenchymal-Chondrocyte-Resting_chondrocyte|wk_08-11 / Celltypes from embryonic and fetal-stage human lung

SEC16B CHRDL2 CASP2 TRIM9 GLG1

8.52e-05182109500a148b1e499bf16325491536d187d4dd6b70c06
ToppCellCF|World / Disease state, Lineage and Cell class

ADAM19 HIVEP2 CD55 ST6GALNAC3 CXCR1

9.68e-051871095eec4d4e4a658e3a61c05745167a1a5e3d39bb43e
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c06-NR4A2|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)

HIVEP2 CD55 AREG NOSIP CACNA1I

9.93e-051881095939790f133eac9c12d08db6ddb5f08f5107844e3
ToppCell3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-bronchial_goblet_cell-Goblet_(bronchial)|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ABCA13 CD55 CP CFB FCGBP

1.04e-04190109523f2ac4da431211084bb6ab0494c2e0b69547cb6
ToppCell3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-bronchial_goblet_cell|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ABCA13 CD55 CP CFB FCGBP

1.04e-0419010953c337374d89e69cc0a78e65a4a7e21db7b050fcd
ToppCell(05)_Secretory-(1)_GFP|(05)_Secretory / shred by cell type by condition

RAPSN CFB FCGBP MAP2K3

1.07e-041001094838340a2b7c76f603e0ef2fe4fd170bd0dbce685
ToppCellCD8+_Memory_T_cell-CV-7|CD8+_Memory_T_cell / cell class, Virus stimulation and cluster

ADAM19 GBF1 HEATR1 ADAM10 GLG1

1.07e-0419110959454f642c3621370fa23640b631301346b300950
ToppCell3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-club_cell-Club_(nasal)-Club_(nasal)_L.0.2.3.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ABCA13 CD55 CP CFB FCGBP

1.07e-041911095529068029fb461df766135576dd0d8b5980f9bc0
ToppCellRA-08._Macrophage|World / Chamber and Cluster_Paper

CD55 AREG TGFBI ST6GALNAC3 MAP2K1

1.12e-0419310955fd22db1825d105709fcc0aa4955c99a117e3c82
ToppCell3'-Distal_airway-Epithelial-Epithelial_transtional-secretory-tracheobronchial_goblet_cell-Goblet_(subsegmental)-Goblet_(subsegmental)_L.0.4.3.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ABCA13 CD55 CP CFB FCGBP

1.18e-0419510952a9a36df1dbc4eac77a8ddbe939ec8a8d6c41464
ToppCell3'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-club_cell-Club_(nasal)-Club_(nasal)_L.0.2.3.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TRIB2 ABCA13 CD55 CP FCGBP

1.18e-0419510953f8ed20ad17afe1545e574e5ca5fe33c3704c7f3
ToppCellSecretory|World / shred by cell class for bronchial biopsy

ABCA13 CD55 CP CFB FCGBP

1.18e-04195109552f8281fe0df67cec3faa780a23ed6343ed5a6ba
ToppCell3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ABCA13 CD55 CP CFB FCGBP

1.21e-041961095c18874f37b90e6afacc562b2082b67ea8a7cb4a4
ToppCell3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-bronchial_goblet_cell-Goblet_(bronchial)-Goblet_(bronchial)_L.0.4.2.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ABCA13 CD55 CP CFB FCGBP

1.21e-0419610952c3fbfbb08cd327cd97b3fa5a6f83b6d50771fb7
ToppCell3'-Broncho-tracheal-Immune_Myeloid-Myeloid_macrophage-elicited_macrophage|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

HIVEP2 ZBTB1 TGFBI MAP2K3 YTHDF3

1.21e-041961095c2bbb48c4aa979b03cb6f4ce9f351f492977c992
ToppCell3'-Broncho-tracheal-Immune_Myeloid-Myeloid_macrophage-elicited_macrophage-Monocyte-derived_macrophage|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

HIVEP2 ZBTB1 TGFBI MAP2K3 YTHDF3

1.21e-04196109564c2abc0087bf2ae547932377f3662e3be1cc63e
ToppCellLung_Parenchyma-Control-Epithelial-Epithelial-Basal_3|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)

CACNA1S HIVEP2 CP PLG QSOX2

1.24e-0419710954f8f23b1ef2eae9d300bd2c1a5cb7ef0163858a1
ToppCellParenchyma_Control_(B.)-Epithelial-TX-Basal_3|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type

CACNA1S HIVEP2 CP PLG QSOX2

1.24e-0419710952cff37f9d33951840a8f52ccbba6ca1a4bbe3ad9
ToppCellBronchial-10x5prime-Epithelial-Epi_alveolar-Dividing_AT2|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations

CELF4 XRCC2 UGT8 ROS1 QSOX2

1.24e-04197109549689a03ab31e53386dbe15c77c09ca3a14ebf4e
ToppCellPCW_13-14-Epithelial-Epithelial_alveolar-distal|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung

CD55 AREG UGT8 ROS1 PRKCZ

1.24e-0419710956852a8ec1397811bbdd1fc625c52ed4fa75a931e
ToppCellLung_Parenchyma-Control-Epithelial-Epithelial-Basal_3-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

CACNA1S HIVEP2 CP PLG QSOX2

1.24e-0419710950f37afad46b94c748a149d9ee681472d7a3e6937
ToppCellTCGA-Colorectal-Primary_Tumor|TCGA-Colorectal / Sample_Type by Project: Shred V9

WNT2 ETV4 TGFBI TTLL4 QSOX2

1.30e-041991095c7d6a8398f2419b726a0461585d1ee0561654e3b
ToppCell5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ABCA13 CD55 CP CFB FCGBP

1.30e-0419910958bf8d7cd774479f065bbbbcb5a4bd1aa91aa0d85
ToppCell10x_3'_v2v3-Non-neoplastic-Myeloid-Mono-Mono_hypoxia-G|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

SLC36A4 CD55 AREG TGFBI MAP2K1

1.30e-041991095880ba91ccecc6633f6daba7822d9200548a8632f
ToppCellTCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma|TCGA-Colorectal / Sample_Type by Project: Shred V9

WNT2 ETV4 TGFBI TTLL4 QSOX2

1.30e-04199109585b3b1ad01368dae4adbc9da7efc148e49992f69
ToppCell5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ABCA13 CD55 CP CFB FCGBP

1.30e-0419910950c060ef64341659f4b1247d0264ac12e53a7e12e
ToppCellCOVID-19-COVID-19_Mild-Lymphocyte-T/NK-dn_T|COVID-19_Mild / Disease, condition lineage and cell class

HIVEP2 WNK1 NOSIP MYLK3 TRIM9

1.30e-041991095f307d4887b28cf60a591439e278fd668409cb104
ComputationalNeighborhood of ORC1L

POLR2A CASP2 XRCC2 TNK2 PSD4

6.21e-0569665MORF_ORC1L
DrugEtoposide

TRIB2 WRN CASP2 CD55 XRCC2 CPS1 ITGB3 AREG LHX2 NR1I2 MTOR PRKCZ MAP2K3 VDAC1 KLHL26

1.19e-0758710815ctd:D005047
DrugPD153035

UPK1A PGGT1B F11 AREG CSK PIK3CB MTOR MAP2K1

1.66e-071271088CID000004705
DrugAC1L1JM9

CASP2 ADAM10 AREG TGFBI CSK PIK3CB MTOR PRKCI PRKCZ MAP2K1 MAP2K3

2.19e-0730410811CID000005103
Druglavendustin A

CACNA1F CACNA1S CASP2 PIK3CB CACNA1I PRKCI MAP2K1 MAP2K3

1.60e-061711088CID000003894
DrugPD158780

AREG CSK TNK2 MAP2K1 MAP2K3

2.57e-06461085CID000004707
Drugmanganese

CACNA1F CACNA1S WNT2 POLR2A WRN CP CPS1 ITGB3 CFB CSK MTOR IL22 UGT8 CACNA1I PRKCI

4.93e-0679110815CID000023930
DrugCinnarizine

CACNA1F CACNA1S CACNA1I

8.54e-0691083DB00568
Drugloperamide

CACNA1F CACNA1S CACNA1I PRKCI PRKCZ TOP3B

1.09e-051051086CID000003954
DrugMibefradil

CACNA1F CACNA1S CACNA1I

1.67e-05111083DB01388
DrugAC1L1DBR

PGGT1B MTOR MAP2K1 MAP2K3

1.76e-05331084CID000002279
DrugEGFR inhibitor

TGFBI CSK PIK3CB MTOR MAP2K1 MAP2K3

2.33e-051201086CID009549299
Drugphorbol acetate myristate

CACNA1F CACNA1S ADAM19 ETV4 ADAM10 ITGB3 AREG TGFBI MYLK3 CSK PIK3CB MTOR TNK2 CACNA1I PRKCI PRKCZ MAP2K1 MAP2K3 TOP3B

2.96e-05139910819CID000004792
DrugAC1NDZBW

WNT2 POLR2A AREG MTOR ADAMTS20 MAP2K1 CXCR1

3.12e-051871087CID004634040
DrugNSC618487

SEC16B RAPSN CASP2 ADAM10 TGFBI MYLK3 CSK PIK3CB TNK2 PRKCI PRKCZ MAP2K1 MAP2K3 VDAC1 CXCR1

3.44e-0593310815CID000005279
Drugcyclophorine

CACNA1F CACNA1S CD55 TGFBI NR1I2 MTOR CACNA1I PRKCI PRKCZ VDAC1

3.58e-0542610810CID000002909
DrugClindamycin hydrochloride [21462-39-5]; Up 200; 8.6uM; MCF7; HT_HG-U133A

CASP2 XRCC2 CPS1 ITGB3 IL22 TNK2 GREB1

3.70e-0519210872219_UP
DrugGo6983

MTOR PRKCI MAP2K1 MAP2K3

3.84e-05401084CID000003499
Drugimatinib

F11 TGFBI CSK PIK3CB MTOR TNK2 CACNA1I ROS1 MAP2K1 MAP2K3

3.88e-0543010810CID000005291
DrugNapelline [5008-52-6]; Down 200; 11.2uM; MCF7; HT_HG-U133A

RAPSN CASP2 XRCC2 WNK1 IL22 GREB1 MAP2K3

3.95e-0519410876084_DN
DrugIopanoic acid [96-83-3]; Down 200; 7uM; MCF7; HT_HG-U133A

ADAM19 ZBTB1 TGFBI FGD1 MAP2K3 TOP3B ZNF614

3.95e-0519410875448_DN
Drug17alpha-estradiol

WNT2 ITGB3 F11 GFPT1 CFB AREG TGFBI NR1I2 PIK3CB MTOR PWP2 OSBPL5 PRKCI PRKCZ GREB1 MAP2K1 MAP2K3 CXCR1

3.96e-05130310818CID000000450
DrugAC1L1G9T

RAPSN TGFBI CSK PIK3CB MTOR PRKCI PRKCZ MAP2K1 MAP2K3 CXCR1

4.11e-0543310810CID000003591
DrugChelidonine monohydrate (+) [476-32-4]; Down 200; 10.8uM; MCF7; HT_HG-U133A

CASP2 XRCC2 ADAM10 LHX2 GREB1 MAP2K3 KLHL26

4.21e-0519610876236_DN
DrugKarakoline [39089-30-0]; Up 200; 10.6uM; HL60; HT_HG-U133A

ADAM19 HIVEP2 CPS1 ANGEL2 FGD1 UGT8 CACNA1I

4.64e-0519910872203_UP
DrugCorticosterone [50-22-6]; Down 200; 11.6uM; PC3; HT_HG-U133A

RAPSN ZNF407 LHX2 PIK3CB TTLL4 ASTN1 CACNA1I

4.64e-0519910874064_DN
DrugCytisine (-) [485-35-8]; Down 200; 21uM; MCF7; HT_HG-U133A

HIVEP2 WNK1 ADAM10 ZBTB1 IL22 FGD1 GREB1

4.79e-0520010872759_DN
DrugY-27632

ETV4 ADAM10 PGGT1B F11 TGFBI PIK3CB PRKCI PRKCZ MAP2K1 MAP2K3

5.07e-0544410810CID000005711
DrugVerapamil

CACNA1F CACNA1S CACNA1I

5.56e-05161083DB00661
Drugprocyanidin B2

MTOR PRKCI PRKCZ MAP2K1

6.14e-05451084CID000122738
DrugAC1L1H7K

PGGT1B AREG PIK3CB PRKCZ MAP2K1 MAP2K3

6.50e-051441086CID000004010
DrugN-methyl-DL-aspartic acid

CACNA1F CACNA1S ADAM10 F11 MYLK3 PIK3CB MTOR CACNA1I PRKCI PRKCZ MAP2K1 MAP2K3

6.53e-0565510812CID000004376
DrugPkcs

WNK1 PIK3CB MTOR PRKCI PRKCZ MAP2K1 MAP2K3

6.71e-052111087CID000164073
Druggenistein

CACNA1F CACNA1S ITGB3 TGFBI CSK PIK3CB MTOR IL22 TET1 PWP2 CACNA1I PRKCI GREB1 MAP2K1 MAP2K3 CXCR1

7.32e-05111710816CID005280961
Drug1n9a

WRN PGGT1B AREG MTOR MAP2K1

9.03e-05951085CID004631604
DrugAC1L1DXE

CACNA1F CACNA1S NR1I2 PIK3CB MTOR CACNA1I PRKCI PRKCZ

9.11e-052991088CID000002548
Drugoleoyl-lysophosphatidic acid

PGGT1B TGFBI CSK PIK3CB MTOR PRKCI MAP2K1 MAP2K3 CXCR1

1.04e-043911089CID000003987
Drug8-bromoguanosine 3',5'-cyclic monophosphate

CACNA1F CACNA1S PIK3CB CACNA1I PRKCI MAP2K1 MAP2K3 TOP3B

1.12e-043081088CID000001915
Diseasehigh grade glioma (implicated_via_orthology)

AREG PIK3CB PRKCI PRKCZ

1.84e-05441054DOID:3070 (implicated_via_orthology)
Diseasewaist-hip ratio

SEC16B TRIB2 RAPSN WNT2 HECTD4 ZNF407 EZH1 WNK1 ITGB3 NOSIP PRMT6 CSK ADAMTS20 DLEC1 MAP2K3

2.91e-05122610515EFO_0004343
DiseaseMYASTHENIC SYNDROME, CONGENITAL, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR DEFICIENCY

RAPSN GFPT1

3.75e-0531052C1837091
Diseaseserum non-albumin protein measurement

TRIB2 RAPSN POLR2A GPX4 CPS1 ITGB3 ACOX2 VDAC1

4.62e-053611058EFO_0004568
DiseaseTimothy syndrome (implicated_via_orthology)

CACNA1F CACNA1S

7.49e-0541052DOID:0060173 (implicated_via_orthology)
Diseasevery low density lipoprotein particle size measurement

RAPSN ADAM10 NOSIP INTS10 PLG

1.16e-041331055EFO_0008594
Diseasefree cholesterol measurement, high density lipoprotein cholesterol measurement

RAPSN OBSL1 CPS1 ADAM10 PRMT6 INTS10 PLG

1.38e-043151057EFO_0004612, EFO_0008591
DiseaseNoonan syndrome (is_marker_for)

F11 PLG

1.86e-0461052DOID:3490 (is_marker_for)
Diseaseceramide measurement

SEC16B ADAM19 RAPSN GPX4 CPS1 UGT8

2.00e-042351056EFO_0010222
Diseasevery low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio

SEC16B RAPSN HECTD4 ADAM10 INTS10 PLG

3.72e-042641056EFO_0008317, EFO_0020944
Diseaseinvasive ductal carcinoma (is_marker_for)

AREG FGD1 PRKCI

3.93e-04401053DOID:3008 (is_marker_for)
Diseaseglioblastoma (is_marker_for)

HEATR1 PIK3CB MAP2K3

5.22e-04441053DOID:3068 (is_marker_for)
Diseasebreast cancer (is_marker_for)

WNT2 CD55 CFB MAP2K1 MAP2K3

5.34e-041851055DOID:1612 (is_marker_for)
DiseaseBreast Carcinoma

CTU2 GPX4 ETV4 XRCC2 ADAM10 AREG PIK3CB MTOR

6.89e-045381058C0678222
Diseasemetabolic syndrome

SEC16B RAPSN HECTD4 INTS10 PLG

7.59e-042001055EFO_0000195
Diseasefree cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement

SEC16B RAPSN ADAM10 PRMT6 INTS10 PLG

7.67e-043031056EFO_0004612, EFO_0020945
Diseaseprostate cancer (is_implicated_in)

CD55 PIK3CB MTOR VDAC1

8.24e-041171054DOID:10283 (is_implicated_in)
Diseaselobe attachment

CACNA1S HIVEP2 CHRDL2 HMCN1 TTLL4

8.86e-042071055EFO_0007667
Diseasephospholipid measurement, high density lipoprotein cholesterol measurement

RAPSN OBSL1 CPS1 ADAM10 INTS10 PLG

1.03e-033211056EFO_0004612, EFO_0004639
Diseasetriglycerides to total lipids in medium HDL percentage

RAPSN INTS10 PLG

1.06e-03561053EFO_0022333
Diseasecholesteryl esters to total lipids in medium HDL percentage

RAPSN INTS10 PLG

1.06e-03561053EFO_0022251
Diseasefactor XI measurement, fibrinogen measurement, tissue plasminogen activator measurement, factor VII measurement

HECTD4 CPS1 F11

1.06e-03561053EFO_0004619, EFO_0004623, EFO_0004694, EFO_0004791
Diseasepsychosis

NALCN TRIM9

1.11e-03141052EFO_0005407
Diseaselevel of Phosphatidylethanolamine (18:1_18:1) in blood serum

RAPSN ADAM10

1.11e-03141052OBA_2045142
Diseaselipid measurement, high density lipoprotein cholesterol measurement

RAPSN OBSL1 CPS1 ADAM10 INTS10 PLG

1.19e-033301056EFO_0004529, EFO_0004612
DiseaseSchizophrenia

CACNA1F ABCA13 CP ITGB3 PIK3CB MTOR TET1 PLG TOP3B MYO16

1.22e-0388310510C0036341
Diseasetriglycerides to total lipids in large HDL percentage

RAPSN INTS10 PLG

1.29e-03601053EFO_0022330
Diseasecholesterol to total lipids in medium HDL percentage

RAPSN INTS10 PLG

1.29e-03601053EFO_0022237
Diseasetriglycerides in small VLDL measurement

RAPSN INTS10 PLG

1.36e-03611053EFO_0022145
Diseasefree cholesterol in HDL measurement

RAPSN INTS10 PLG

1.36e-03611053EFO_0022264
Diseasedisease progression measurement

TRIB2 HIVEP2 POLR2A

1.36e-03611053EFO_0008336
Diseasetriglycerides in small HDL measurement

RAPSN INTS10 PLG

1.42e-03621053EFO_0022158
Diseasephospholipids in large VLDL measurement

RAPSN INTS10 PLG

1.42e-03621053EFO_0022169
Diseasetriglycerides to total lipids in very large HDL percentage

RAPSN INTS10 PLG

1.42e-03621053EFO_0022339
Diseaseneutrophil collagenase measurement

ABCA13 CFB

1.46e-03161052EFO_0008248
DiseaseMalignant neoplasm of breast

CTU2 GPX4 ETV4 XRCC2 WNK1 ADAM10 AREG PIK3CB MTOR DLEC1 CPSF3

1.55e-03107410511C0006142
Diseasefactor XI measurement, Ischemic stroke

HECTD4 F11

1.65e-03171052EFO_0004694, HP_0002140
Disease3-hydroxypropylmercapturic acid measurement

CELF4 WNT2 WNK1 PIK3CB ADAMTS20 PRKCI

1.65e-033521056EFO_0007014
Diseasevenous thromboembolism, fibrinogen measurement

HECTD4 CPS1 F11

1.78e-03671053EFO_0004286, EFO_0004623
DiseaseAge-related macular degeneration

CFB HMCN1

1.85e-03181052cv:C0242383
Diseaseschizophrenia (implicated_via_orthology)

HIVEP2 MTOR ASTN1

1.86e-03681053DOID:5419 (implicated_via_orthology)
Diseasefatty acid measurement, linoleic acid measurement

RAPSN PLG MAP2K3

1.86e-03681053EFO_0005110, EFO_0006807
Diseasetriglycerides to phosphoglycerides ratio

RAPSN INTS10 PLG

1.86e-03681053EFO_0022327
Diseasefree cholesterol in large VLDL measurement

RAPSN INTS10 PLG

1.86e-03681053EFO_0022265
Diseasetriglycerides:total lipids ratio, low density lipoprotein cholesterol measurement

RAPSN ADAM10 INTS10 PLG

2.06e-031501054EFO_0004611, EFO_0020947
Diseaselevel of Phosphatidylethanolamine (18:0_20:4) in blood serum

RAPSN ADAM10

2.06e-03191052OBA_2045140
Diseaselevel of Sphingomyelin (d38:2) in blood serum

RAPSN AREG

2.06e-03191052OBA_2045179
Diseasepolycystic kidney disease (biomarker_via_orthology)

CFB MTOR

2.06e-03191052DOID:0080322 (biomarker_via_orthology)
Diseasebody surface area

SEC16B CPS1 WNK1 ITGB3 MTOR OSBPL5 DLEC1 PSD4

2.13e-036431058EFO_0022196
Diseasetriglycerides to total lipids in small HDL percentage

RAPSN INTS10 PLG

2.19e-03721053EFO_0022336
Diseasephospholipids in large HDL measurement

RAPSN INTS10 PLG

2.27e-03731053EFO_0022190
Diseasetotal lipids in large HDL

RAPSN INTS10 PLG

2.36e-03741053EFO_0022189
DiseaseNon-Small Cell Lung Carcinoma

AREG MTOR ROS1 MAP2K1

2.38e-031561054C0007131
Diseaseserum IgG glycosylation measurement

MKRN3 HIVEP2 WRN ZNF407 ITGB3 SUMF1 CACNA1I

2.70e-035231057EFO_0005193
Diseasemonounsaturated fatty acids; 16:1, 18:1 measurement

RAPSN INTS10 PLG

2.74e-03781053EFO_0022187
DiseaseMammary Carcinoma, Human

CTU2 GPX4 ETV4 XRCC2 ADAM10 AREG MTOR

2.76e-035251057C4704874
DiseaseMammary Neoplasms, Human

CTU2 GPX4 ETV4 XRCC2 ADAM10 AREG MTOR

2.76e-035251057C1257931
DiseaseMammary Neoplasms

CTU2 GPX4 ETV4 XRCC2 ADAM10 AREG MTOR

2.82e-035271057C1458155
Diseasefree cholesterol in large HDL measurement

RAPSN INTS10 PLG

2.85e-03791053EFO_0022157
Diseasecreatinine measurement

CACNA1S RAPSN CPS1 AREG TNK2 DLEC1 PRKCZ RPL3L QSOX2 PSD4

2.91e-0399510510EFO_0004518
Diseasecholesterol in large HDL measurement

RAPSN INTS10 PLG

2.95e-03801053EFO_0021900
Diseasetriglyceride measurement, low density lipoprotein cholesterol measurement

RAPSN ADAM10 INTS10 PLG

2.97e-031661054EFO_0004530, EFO_0004611
Diseasetriglyceride measurement, high density lipoprotein cholesterol measurement

GBF1 RAPSN ADAM10 INTS10 PLG

3.02e-032741055EFO_0004530, EFO_0004612
Diseaseinsulin sensitivity measurement

RAPSN CPS1

3.02e-03231052EFO_0004471
Diseasecholesterol:total lipids ratio, high density lipoprotein cholesterol measurement

SEC16B GBF1 RAPSN ADAM10 INTS10

3.12e-032761055EFO_0004612, EFO_0020943
Diseasehigh density lipoprotein particle size measurement

RAPSN ADAM10 INTS10 PLG

3.24e-031701054EFO_0008592
DiseaseMyasthenic Syndromes, Congenital

RAPSN GFPT1

3.29e-03241052C0751882
Diseasenighttime rest measurement

SEC16B MYOM1

3.29e-03241052EFO_0007827
Diseaselevel of Phosphatidylethanolamine (16:0_18:2) in blood serum

RAPSN ADAM10

3.29e-03241052OBA_2045136
DiseaseAutism Spectrum Disorders

CHD8 ITGB3 TET1

3.50e-03851053C1510586

Protein segments in the cluster

PeptideGeneStartEntry
TGYKREHINLGCDMD

VDAC1

116

P21796
SFGCNYGMESRHREL

BTN2A3P

561

Q96KV6
AHDKRGRYGTLFTMD

TGFBI

481

Q15582
VDLHGHASKRGCFMY

AGBL5

431

Q8NDL9
EMCRRACGGHGYSKL

ACOX2

406

Q99424
GHSRKENIFMYGCDG

AGBL3

461

Q8NEM8
ESLTKYFHGFVAMCR

CHD8

1841

Q9HCK8
YFGERCGEKSMKTHS

AREG

176

P15514
GYCVEGTLAKHIMSE

CPSF3

356

Q9UKF6
GGCADHSVFERMRKY

ADAM10

171

O14672
VMTGTKCGYNHICFE

ADAM19

626

Q9H013
CNVHGLMSSSFYGKV

ABCA13

1841

Q86UQ4
SCDGKVEHYRIMYHA

CSK

121

P41240
SLGYHCEYKMRTGRK

ANGEL2

236

Q5VTE6
CDGFLALMGVYHEKA

CALML6

91

Q8TD86
GLSPMKDSSGCYDRH

ASTN1

641

O14525
GQGYRTLDIHCMKYS

ADAMTS20

921

P59510
VAEGMGYLESKRFIH

TNK2

236

Q07912
DVTGCASMYLHTEGF

ETV4

271

P43268
GAFYSDGEISICMEH

MAP2K1

131

Q02750
LGCLVTAHSEMGRYK

RAPSN

46

Q13702
MRRYVHTFFGCKECG

QSOX2

466

Q6ZRP7
TCHFALGEYRMTCEK

INTS10

501

Q9NVR2
MTRHGKNCTAGAVYT

NOSIP

1

Q9Y314
NVECLTTDHYTGGMK

CP

696

P00450
KGHESCMGAVVSEYF

CFB

506

P00751
AELCPGDKYEMRSHG

OBSL1

1846

O75147
GRMHKTCYFLGSDME

CACNA1F

261

O60840
LDSEGHIKLTDYGMC

PRKCI

386

P41743
CSHYQGIKSEDRGMS

GREB1

1426

Q4ZG55
EGVTLLHMACASGYK

MYO16

221

Q9Y6X6
GFCKLSGYHRADVMQ

KCNH5

46

Q8NCM2
GMARYHVTVCTGELE

LOXHD1

551

Q8IVV2
YACNKGFTMIGEHSI

CD55

251

P08174
GDHFGMKDSLVYCRA

LHX9

171

Q9NQ69
SKHSCTLVMEYVDGG

MYLK3

581

Q32MK0
TTGDHFGMKDSLVYC

LHX2

151

P50458
DKATGYHFNVMTCEG

NR1I2

46

O75469
MFCLFHGKRYSPGES

CHRDL2

31

Q6WN34
GRFSTYFHALMEGCL

HECTD4

2826

Q9Y4D8
MKCYFTDHRGEQSPT

FAM170B

1

A6NMN3
GLYRCMAANTAGDHK

HMCN1

1801

Q96RW7
TEYVKACDGIGGAMH

ERVK-5

506

Q9HDB9
GKGYMVSCLVDHRGN

GLG1

196

Q92896
ACFGEGIHTAFLKAM

CPS1

1336

P31327
VICKTFHSMAYGHIG

FBH1

506

Q8NFZ0
YALGGRMDHVDRCFD

KLHL26

511

Q53HC5
MTTYGAFLHKGSFCR

CACNA1S

851

Q13698
DGHRFDFMGTCVYVL

FCGBP

3666

Q9Y6R7
MHIFGCKFSLRTDTG

CACNA1I

781

Q9P0X4
DMCGFVIAHLLGVKY

UGT8

141

Q16880
CYGFTLRTLFKAHMG

CXCR1

221

P25024
HKMICAGYREGGKDA

F11

556

P03951
VKQHYGVDMSCLEGF

PRMT6

211

Q96LA8
DFSCVRYKGEMCSGH

ITGB3

551

P05106
SGFRKCAMISAHYGL

GBF1

956

Q92538
GTLITHCYKDLGFMD

HEATR1

176

Q9H583
TCYGIVHIAGEFKDM

MMGT1

56

Q8N4V1
GHMVNLDKYRGFVCI

GPX4

51

P36969
ILHKVECTGYALGFM

DLEC1

1416

Q9Y238
APGTEFHRCKEMSEY

CASP2

421

P42575
AHGYSKVMTGDSCTR

CTU2

256

Q2VPK5
YAHCKGILYGTMTLE

OSBPL5

536

Q9H0X9
EGHVKMCDFGISGYL

MAP2K3

201

P46734
KEISFGGCLSHMFFI

OR52E8

96

Q6IFG1
GLDGNYRITCHTVME

MTOR

2391

P42345
HAYFGICGLSLMEES

PGGT1B

321

P53609
KSVLIMGRGYHYATC

GFPT1

556

Q06210
FLGYKAGMTHTLREV

RPL3L

46

Q92901
IFKGHMVAGYACQVD

CDC40

501

O60508
NSVICSFLHYMEKGG

FGD1

821

P98174
RGMVLYFLKQGEDHC

PSD4

811

Q8NDX1
GIHVYGMINDTYCKT

ST6GALNAC3

231

Q8NDV1
CGTYHAGMSFSTRKD

WRN

791

Q14191
GEKLFHGVSMSERCY

IL22

76

Q9GZX6
EAYCRGSVGHMKVLS

PIK3CB

696

P42338
MHCSGENYDGKISKT

PLG

186

P00747
DRVKKGGSYMCHRSY

SUMF1

326

Q8NBK3
SMDYSRCGHGEEQKL

TET1

671

Q8NFU7
TGMHKGCAFLTYCER

CELF4

91

Q9BZC1
SVCGHVMTLDFLGKY

TOP3B

56

O95985
GHFCGVAEMKSVVDY

YTHDF3

471

Q7Z739
RGYDTSHVTRMTKCG

WNT2

311

P09544
MQCYLTRDKHGVDKG

TULP2

286

O00295
VCFRGESCMYLHGDI

MKRN3

251

Q13064
LAGGMSKFVCIYHVR

PWP2

621

Q15269
SSRCEYLSHMGPVKG

TOMT

106

Q8WZ04
ERSYGDMHSFVRTCK

TRIB2

131

Q92519
QTGYKVERHMCDGDI

POLR2A

441

P24928
CYAKVVMVNGDHRIG

EZH1

696

Q92800
CISSRFHYSVKMGDR

PRSS42P

121

Q7Z5A4
VDISKGCVYLERMHF

ROS1

2061

P08922
NEEGCRLGHMDYLFT

UPK1A

201

O00322
RLGHMDYLFTKGCFE

UPK1A

206

O00322
GKGLVEAAHFCYLMA

SEC16B

556

Q96JE7
GTGKTEMLYHLTARC

XRCC2

51

O43543
YVGKETMCTVDGLHF

TRIM9

491

Q9C026
MDVHLYTCGICGAKF

ZBTB1

681

Q9Y2K1
MELCGGSEYGKTSHL

ZNF658

491

Q5TYW1
IMHTGEKRYECDDCG

ZFP62

161

Q8NB50
YYTVTKGDMERHCAT

ZNF407

886

Q9C0G0
GMREYKCHVCGVAFV

ZNF407

1591

Q9C0G0
VESGYVCEGDHKTMA

WNK1

541

Q9H4A3
ECGKGFTMKRYLIAH

ZNF614

291

Q8N883
ISCLSSLKHGGEYFM

HIVEP2

661

P31629
CYKGFHMGVVSDSAP

TTLL4

1071

Q14679
CGKAFTQYSGLSMHV

ZNF426

341

Q9BUY5
LATLGYMCFHDEIKG

SLC36A4

321

Q6YBV0
MELCGGSEYGKTSHL

ZNF658B

251

Q4V348
ADGHIKLTDYGMCKE

PRKCZ

386

Q05513
CYEMERLHNGGDVTF

NALCN

1516

Q8IZF0
RYGMHTLEINGCDFE

MYOM1

331

P52179
HEGIMYFVEKCEAGT

MYOM1

666

P52179